Dr. Robert K. Naviaux, M.D., Ph.D.

Professor of Genetics, Departments of Medicine and Pediatrics at UCSD. Director of a core laboratory for metabolomics.

Follow Robert K. on Social
Profile picture of dr-robert-k-naviaux-m-d-ph-d

Dr. Robert Naviaux, MD, Ph.D., is the founder and co-director of the Mitochondrial and Metabolic Disease Center (MMDC) at UCSD. Additionally, he is a professor of medicine, pediatrics, pathology, and genetics there. Plus, he heads a laboratory for metabolomics research.

Dr. Naviaux is an experienced professional in human genetics and mitochondrial medicine who has co-founded the Mitochondrial Medicine Society (MMS) and served as its former president.

Dr. Naviaux is the renowned discoverer of Alpers syndrome—the Mendelian form of mitochondrial disease—and the developer of the first DNA test to diagnose it. His laboratory also discovered the first mitochondrial DNA (mtDNA) mutations that cause genetic forms of autism and diagnosed features of cell danger response (CDR).

The first clinical trial he directed, which was approved by the FDA, studied suramin as a possible new treatment for autism spectrum disorder.

His lab has developed new methods in metabolomics and environmental toxicology. These have shown that many chronic disorders like ASD and ME/CFS have a metabolic signature that can be used for diagnosis. They also provide fresh insights into treatment.

Book Foreword authored by Dr. Robert K. Naviaux, M.D., Ph.D.